Company Name
Canaan Research & Investment, s.l.
Activity
Biotech Holding focused on different health areas: diagnosis, neurological diseases, nutraceuticals and dermatology.
CIF
B87162335
Sector
Biotechnology
Address
Avda. Industria, nº 4, edificio 1, planta baja, local D (Natea Business Park) - ALCOBENDAS (Madrid)
EPM Joining Date
22/09/2021
Creation Date
03/12/2014
Founders Tres socios fundadores: Enrique Sainz Martínez, Juan José Montoya Miñano, Alfonso Ortega Gallego. Actualmente, además de los 3 socios fundadores, la empresa cuenta con 12 accionistas más en Canaan. Cada una de las empresas participadas por Canaan en más del 50% tiene además sus propios accionistas
Auditor
AMS Asociados
Investors email contact
esainz@canaanrd,com
Presenting Partner
Foro Capital Pymes
Company profile
Biotech Holding focused on molecular diagnosis, CNS pathologies, dermatology & nutraceutical areas, with a focus on projects of high innovative intensity from research centers, universities and public foundations for their development and traslationality to the current market.
On the Road to BME Growth
Relevant data
| (thousand of Euros) | 2019 | 2020 |
|---|---|---|
| Net worth | 310 | 310 |
| Net business turnover | 252 | 278 |
| Financial debt | 31 | 427 |
| Ebitda | 35 | 41 |
| Net Profit | 17 | 34 |
| Average number of employees | 15 | 15 |
Investment Rounds
| Date | Status | Amount | Minimum Ticket |
|---|---|---|---|
| 04-10-2021 | Closed | 1.500.000 | 10000,00 |
| 01-02-2022 | Open | 3.000.000 | 25000,00 |
Business Model
Development of biotechnological projects with high potential (and from public research centers and institutions, universities and foundations), for through a business structure, to obtain, validate and commercialize new biotechnological products that meet unmet needs in the Biotech Industry and improve people's quality of life.
Competitive advantage
CANAAN uses the Open Innovation model through which the company cooperates and works with its external environment through partnerships with research centers and public institutions, taking advantage of the knowledge generated in these centers, with the aim of generating all the subsequent development that transform this knowledge and R&D towards highly innovative products and licenses that can be transferred to the market.
The Open Innovation model has as main advantages:
- Cost reduction and optimization.
- Maximization of technology transfer with research centers and companies.
- Talent attraction.
Scalability
Having in our portfolio marketable technologies and products in some cases in the market or in advanced stage of development allows us to ensure scalability both at the territorial level, since the target objective of our companies is obviously international, and in terms of the scope of the sector in which Canaan operates, the health sector is an area of maximum impact with a continuous market growth.
